- Home
- IAUX vs AMLX Comparison
IAUX vs AMLX Comparison
Compare IAUX & AMLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IAUX
- AMLX
- Stock Information
- Founded
- IAUX 2020
- AMLX 2014
- Country
- IAUX United States
- AMLX United States
- Employees
- IAUX N/A
- AMLX N/A
- Industry
- IAUX
- AMLX Biotechnology: Pharmaceutical Preparations
- Sector
- IAUX
- AMLX Health Care
- Exchange
- IAUX Nasdaq
- AMLX Nasdaq
- Market Cap
- IAUX 408.0M
- AMLX 481.9M
- IPO Year
- IAUX N/A
- AMLX 2022
- Fundamental
- Price
- IAUX $0.67
- AMLX $5.19
- Analyst Decision
- IAUX
- AMLX Buy
- Analyst Count
- IAUX 0
- AMLX 7
- Target Price
- IAUX N/A
- AMLX $7.60
- AVG Volume (30 Days)
- IAUX 15.9M
- AMLX 1.7M
- Earning Date
- IAUX 11-12-2024
- AMLX 11-07-2024
- Dividend Yield
- IAUX N/A
- AMLX N/A
- EPS Growth
- IAUX N/A
- AMLX N/A
- EPS
- IAUX N/A
- AMLX N/A
- Revenue
- IAUX $52,944,000.00
- AMLX $196,485,000.00
- Revenue This Year
- IAUX $2.31
- AMLX N/A
- Revenue Next Year
- IAUX $123.01
- AMLX $149.49
- P/E Ratio
- IAUX N/A
- AMLX N/A
- Revenue Growth
- IAUX 30.02
- AMLX N/A
- 52 Week Low
- IAUX $0.34
- AMLX $1.58
- 52 Week High
- IAUX $1.88
- AMLX $19.95
- Technical
- Relative Strength Index (RSI)
- IAUX 40.06
- AMLX 50.53
- Support Level
- IAUX $0.34
- AMLX $5.09
- Resistance Level
- IAUX $1.09
- AMLX $5.88
- Average True Range (ATR)
- IAUX 0.08
- AMLX 0.61
- MACD
- IAUX -0.03
- AMLX -0.20
- Stochastic Oscillator
- IAUX 43.98
- AMLX 22.96
About IAUX i-80 Gold Corp.
i-80 Gold Corp is a well-financed gold and silver producer engaged in the exploration, development, and production of gold, silver, and poly-metallic deposits. The Company's principal assets include the Ruby Hill Mine, Lone Tree Mine, Granite Creek Mine, and McCoy-Cove Project.
About AMLX Amylyx Pharmaceuticals Inc.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder.